Wisdom teeth: Platelet-Rich Fibrin reduces the risk of alveolar osteitis by 5-fold

Optimising post-operative outcomes following mandibular wisdom tooth extraction: what is the real weight of PRF?

The use of PRF (platelet-rich fibrin) in oral surgery has established itself as an autologous approach aimed at modulating inflammation, stimulating angiogenesis, and promoting tissue regeneration after tooth extraction. Despite its growing adoption, clinical evidence regarding its actual efficacy remains heterogeneous. A major point of contention persists: the comparative performance between different PRF subtypes, notably L-PRF (leukocyte-PRF) and A-PRF (advanced PRF), whose clinical superiority is not yet clearly established.

This systematic review and meta-analysis, based on the examination of 28 randomised controlled trials, precisely evaluates the impact of PRF on post-operative outcomes following mandibular third molar extraction. The objective is to provide a rigorous answer regarding the reduction of pain, trismus, oedema, analgesic consumption, and the risk of dry socket.

The study tests the hypothesis that local application of PRF outperforms natural healing via a fibrin clot. It also confronts available data to determine whether variations in preparation protocols influence the observed clinical benefits. This synthesis thus offers a crucial overview for the practitioner faced with managing immediate post-operative complications in the practice.

Methodology: systematic review and meta-analysis

This study is a systematic review and meta-analysis conducted according to PRISMA standards, evaluating the clinical efficacy of using platelet-rich fibrin (PRF) during mandibular third molar extraction. The authors performed an exhaustive literature search in the PubMed, EMBASE, and Cochrane Library databases, covering the period from the inception of these databases until March 2026.

The inclusion protocol focused on randomised controlled trials (RCTs) comparing the local application of PRF to natural clot healing. In total, 28 studies were selected for the synthesis.

• Primary outcome measure: post-operative pain.
• Secondary outcome measures: incidence of dry socket (alveolar osteitis), oedema, trismus, analgesic consumption, and bone density parameters.
• Risk of bias assessment: performed using the RoB 2 tool.
• Statistical analysis: meta-analyses were performed using random-effects models. Heterogeneity between included studies was systematically quantified by the I² statistic.

Although data concerning bone density were analysed descriptively due to high methodological heterogeneity in the imaging techniques used across six of the included studies, clinical results such as pain and dry socket allowed for a robust quantitative pooling. The study also distinguishes the performance of PRF subtypes (L-PRF and A-PRF), although data specific to A-PRF are limited to a single clinical trial.

Analysis of results: PRF in wisdom tooth surgery

This meta-analysis, covering 28 randomised controlled trials, confirms the clinical value of PRF for managing post-operative outcomes following mandibular third molar extraction. The compiled data demonstrate a significant reduction in major post-surgical complications.

The impact on dry socket is particularly marked, with a relative risk (RR) of 0.17, demonstrating the robust efficacy of the biomaterial in preventing this painful complication. The benefit regarding trismus is consistent across all temporal measurement points evaluated in the included studies.

Regarding bone healing, the descriptive analysis of six studies reveals a consistent trend in favour of PRF. However, the major methodological heterogeneity of the imaging techniques used prevented any quantitative statistical aggregation of these data. Similarly, the effect on post-operative oedema remains inconsistent, showing only limited short-term benefits.

An important distinction emerges regarding the type of PRF used: L-PRF presents more homogeneous results across the various clinical parameters than A-PRF. It should be noted, however, that the evidence concerning A-PRF is limited to a single clinical trial, which restricts the scope of this comparison. The heterogeneity observed in certain statistical models is largely attributed to variations in centrifugation protocols and clinical evaluation methods between the source studies.

Confirmed efficacy on post-operative recovery

This meta-analysis, covering 28 randomised clinical trials, confirms the therapeutic value of using PRF (leucocyte-PRF or L-PRF) during the extraction of mandibular third molars. The data show a significant reduction in the risk of dry socket (RR = 0.17; 95% CI: 0.06–0.49), as well as a tangible decrease in post-operative pain from D1 to D7 and analgesic consumption between D2 and D3. Trismus is also improved at all evaluation time points, although the impact on oedema remains modest and inconsistent.

Limitations and nuances

The weak point of this synthesis lies in the major methodological heterogeneity observed between the source studies, particularly regarding PRF preparation protocols and evaluation methods. While L-PRF shows robust and consistent effects, data concerning A-PRF (Advanced PRF) remain limited to a single trial, preventing any solid head-to-head comparison between the variants. Furthermore, although the six studies that evaluated bone density report a trend favorable to PRF, the variability of imaging techniques did not allow for a pooled quantitative analysis.

Implications for the practitioner

These results validate the integration of L-PRF as an autologous biomaterial of choice to optimise healing after complex extractions, in particular to prevent post-operative septic complications.

Summary of the benefits of PRF after 3rd molar extraction

This meta-analysis, synthesising 28 randomised clinical trials, demonstrates that the application of PRF significantly decreases the incidence of alveolar osteitis (RR = 0.17; 95% CI: 0.06–0.49). PRF improves post-operative comfort through a notable reduction in pain over 7 days, a decrease in analgesic consumption on days 2 and 3, as well as a consistent improvement in trismus.

In practical terms, for the practitioner:

• Reduction of complications: The systematic use of L-PRF in the post-extraction socket is a proven strategy to limit dry sockets.
• Priority to L-PRF: To date, clinical evidence is more solid for L-PRF than for A-PRF; therefore, favour L-PRF protocols whose efficacy is better documented.
• Analgesic benefit: Anticipate better management of immediate post-operative recovery, allowing for a reduction in medication prescription during the first 72 hours.

Glossary

Platelet-Rich Fibrin (PRF): Autologous material used to optimise post-extraction healing via the modulation of inflammation, the promotion of angiogenesis, and the stimulation of tissue regeneration.

L-PRF (Leukocyte-Platelet-Rich Fibrin): Subtype of PRF containing leukocytes, having demonstrated, according to the meta-analysis, more consistent efficacy on post-operative recovery parameters than other variants.

A-PRF (Advanced Platelet-Rich Fibrin): PRF variants whose specific clinical efficacy remains to be supported, as current comparative data with L-PRF are limited to a single clinical trial in the synthesis.

Dry socket (AO): Post-extraction complication whose incidence is significantly reduced by the local application of PRF, with a relative risk (RR) of 0.17 according to the compiled data.

Trismus: Limitation of post-operative mouth opening; the studies included in the review indicate a significant improvement in this symptom at all check-points evaluated in patients treated with PRF.

Random-effects models: Statistical approach used in this meta-analysis to synthesise data from the 28 included studies, taking into account the methodological heterogeneity inherent in PRF preparation protocols.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always checking with the original source article. Delynov disclaims any liability regarding the use of this information. This document is not intended for patients or the general public.